iRhythm Technologies to Present at the 42nd Annual William Blair Growth Stock Conference
iRhythm Technologies, a leader in digital health care, announced its participation in the 42nd Annual William Blair Growth Stock Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iRhythm Technologies, a leader in digital health care, announced its participation in the 42nd Annual William Blair Growth Stock Conference. The presentation is scheduled for June 8, 2022, at 2:40 p.m. Central Time. Interested parties can access the live and archived webcast via the company’s website.
iRhythm specializes in innovative cardiac care solutions, using wearable biosensor devices and advanced data analytics to improve the diagnosis of cardiac arrhythmias.
Details
News Market Reaction – IRTC
The recorded move for IRTC in the trading session of this news was +0.96%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, May 25, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the company will be participating in the upcoming 42nd Annual William Blair Growth Stock Conference.
iRhythm’s management is scheduled to present on Wednesday, June 8 at 2:40 p.m. Central Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: www.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a leading digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change the clinical management of patients.
Investor Relations Contact
Stephanie Zhadkevich
(919) 452-5430
stephanie.zhadkevich@irhythmtech.com
iRhythm Media Contact
Morgan Mathis
(310) 528-6306
irhythm@highwirepr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.